Anthos Therapeutics develops advanced anticoagulant therapies designed to reduce the risk of bleeding in patients with thrombotic disorders. The company focuses on high-need conditions, such as atrial fibrillation and cancer-associated thrombosis, leveraging its deep expertise in hemostasis and cardiovascular biology.
Its lead drug candidate is built on cutting-edge science, designed to provide safer anticoagulation for millions of patients globally. Anthos also conducts extensive clinical research to validate the safety and efficacy of its therapies.
What Is Anthos Therapeutics and What Does It Do?
Anthos Therapeutics, founded in 2019 by Paris Panayiotopoulos and Jonathan Freeman, is headquartered in Cambridge, United States. The company develops novel anticoagulants designed to treat thrombosis more safely by reducing the bleeding complications associated with current therapies.
Focused on atrial fibrillation and cancer-associated thrombosis, Anthos leverages deep clinical expertise and research in hemostasis to address significant unmet patient needs.
Anthos Therapeutics employs 14 people and continues to advance next-generation cardiovascular therapies, supported by leading investors and pharmaceutical partners
How Much Funding Has Anthos Therapeutics Raised?
1. Private Equity Round
- Amount Raised: $250M
- Date: February 2019
- Lead Investors: Blackstone, Novartis
- Motivation: To launch the company and advance the development of next-generation anticoagulant therapies with improved safety profiles.
Total Funding Raised: $250 MIllion
Latest Funding Date: February 2019
Key Investors
1. Blackstone Life Sciences
- Details: A global leader in life sciences investing, backing companies developing breakthrough therapies with enormous medical impact.
- Investment Focus Areas: Biotech, therapeutics, cardiovascular diseases.
- Notable Investments: Anthos Therapeutics, Reata Pharma, Cryoport.
2. Novartis
- Details: A global pharmaceutical company known for developing innovative therapies across oncology, immunology, and cardiovascular disease.
- Investment Focus Areas: Drug development, biologics, cardiovascular medicine.
- Notable Investments: Anthos Therapeutics, Alnylam, and Moderna collaborations.
3. Nan Fung Life Sciences (via ecosystem involvement)
- Details: A major health sciences investor with a diversified global portfolio in cutting-edge therapeutics.
- Investment Focus Areas: Gene therapy, cardiovascular disorders, oncology.
- Notable Investments: Tessera, Keros Therapeutics.
4. F-Prime Capital (industry presence)
- Details: A global venture capital firm investing in transformative biotech and healthcare technologies.
- Investment Focus Areas: Therapeutics, clinical biotech, and medical breakthroughs.
- Notable Investments: Denali Therapeutics, Beam Therapeutics.
Where Is Anthos Therapeutics’ Headquarters?
Anthos Therapeutics is headquartered in Cambridge, Massachusetts, a globally recognized biotech hub offering access to world-class research institutions, clinical trial networks, and top-tier life sciences talent.
What’s Next for Anthos Therapeutics?
Anthos Therapeutics aims to advance its lead anticoagulant through late-stage clinical trials, demonstrating superior safety, particularly a reduced bleeding risk. With strong backing from Blackstone and partnership strength from Novartis, the company is positioned to bring a next-generation therapy to millions of patients who cannot tolerate current anticoagulants.
Get Investor & Funding Insights with TexAu
TexAu helps sales and business teams uncover detailed fundraising information on companies like Anthos Therapeutics. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.
Sign Up for Free on TexAu and start uncovering detailed funding insights that give your business a competitive edge.
